$0.77
-0.03 (-3.91%)
Open$0.78
Previous Close$0.80
Day High$0.79
Day Low$0.73
52W High$1.55
52W Low$0.20
Volume—
Avg Volume76.79M
Market Cap44.96M
P/E Ratio—
EPS$-0.65
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,542.6% upside
Current
$0.77
$0.77
Target
$20.24
$20.24
$11.64
$20.24 avg
$22.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.82M | 7.64M | 6.13M |
| Net Income | -1,043,017 | -954,590 | -792,337 |
| Profit Margin | -13.3% | -12.5% | -12.9% |
| EBITDA | -1,028,959 | -906,364 | -702,614 |
| Free Cash Flow | -801,636 | -705,541 | -523,657 |
| Rev Growth | -3.5% | +15.6% | +20.8% |
| Debt/Equity | 1.41 | 1.39 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |